RUBY Rubius Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

RUBY [NASD]

Rubius Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.23	Insider Own	10.06%	Shs Outstand	80.48M	Perf Week	-15.16%
Market Cap	377.99M	Forward P/E	-	EPS next Y	-2.01	Insider Trans	0.00%	Shs Float	73.31M	Perf Month	-1.29%
Income	-177.80M	PEG	-	EPS next Q	-0.49	Inst Own	98.30%	Short Float	11.40%	Perf Quarter	-17.30%
Sales	-	P/S	-	EPS this Y	-85.20%	Inst Trans	2.09%	Short Ratio	45.32	Perf Half Y	-32.99%
Book/sh	2.55	P/B	1.80	EPS next Y	3.40%	ROA	-46.80%	Target Price	-	Perf Year	-50.70%
Cash/sh	2.87	P/C	1.60	EPS next 5Y	-	ROE	-69.60%	52W Range	3.35 - 14.44	Perf YTD	-51.68%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-68.21%	Beta	-
Dividend %	-	Quick Ratio	8.40	Sales past 5Y	-	Gross Margin	-	52W Low	37.01%	ATR	0.37
Employees	199	Current Ratio	8.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	37.87	Volatility	7.40% 7.55%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	6.40%	Profit Margin	-	Rel Volume	0.79	Prev Close	4.68
Shortable	Yes	LT Debt/Eq	0.36	Earnings	Aug 10 BMO	Payout	-	Avg Volume	184.36K	Price	4.59
Recom	2.60	SMA20	-10.73%	SMA50	-9.03%	SMA200	-24.10%	Volume	146,341	Change	-1.92%

Mar-13-20

Downgrade

SVB Leerink

Outperform → Mkt Perform

$19 → $4

Mar-13-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Jan-31-20

Downgrade

JP Morgan

Overweight → Neutral

Sep-10-19

Initiated

Robert W. Baird

Underperform

Jun-26-19

Initiated

H.C. Wainwright

Buy

$40

May-31-19

Initiated

Guggenheim

Buy

Aug-13-18

Initiated

Morgan Stanley

Overweight

$37

Aug-13-18

Initiated

JP Morgan

Overweight

$28

Aug-13-18

Initiated

Jefferies

Buy

$40

Oct-15-20 08:00AM	Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancers Annual Meeting GlobeNewswire
Oct-13-20 08:19AM	Are Insiders Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Stock? Simply Wall St.
Sep-29-20 04:01PM	Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit GlobeNewswire
Sep-28-20 08:00AM	Rubius Therapeutics Appoints Jose Carmona as Chief Financial Officer GlobeNewswire
Sep-22-20 06:55AM	3 High-Risk, High-Reward Stocks to Add to Your Watch List Motley Fool
Sep-08-20 04:01PM	Rubius Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire
Aug-10-20 08:00AM	Rubius Therapeutics Reports Second Quarter 2020 Financial Results and Positive Progress Across Pipeline GlobeNewswire +9.65%
Aug-03-20 04:01PM	Rubius Therapeutics to Announce Second Quarter 2020 Financial Results GlobeNewswire
Jul-07-20 08:00AM	Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing PR Newswire
Jun-30-20 08:00AM	Rubius Therapeutics Provides Update on Clinical Trial Progress for its Lead Oncology Product Candidate RTX-240 and Announces Planned Leadership Transition GlobeNewswire -5.38%
Jun-22-20 08:00AM	Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic Oncology Product Candidate for HPV-Positive Cancers, at the American Association of Cancer Research Virtual Annual Meeting II GlobeNewswire
Jun-01-20 11:31AM	Hedge Funds Are Selling Rubius Therapeutics, Inc. (RUBY) Insider Monkey
May-28-20 08:00AM	Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity PR Newswire
May-26-20 04:01PM	Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference GlobeNewswire
May-15-20 08:00AM	Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting GlobeNewswire -6.67%
May-12-20 06:00AM	Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting GlobeNewswire
May-11-20 08:00AM	Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update GlobeNewswire
May-07-20 08:00AM	Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors GlobeNewswire
May-04-20 04:01PM	Rubius Therapeutics to Announce First Quarter 2020 Financial Results GlobeNewswire
Apr-29-20 08:00AM	Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting GlobeNewswire +6.74%
Apr-16-20 09:23AM	CEO, President & Director Pablo Cagnoni Just Bought A Handful Of Shares In Rubius Therapeutics, Inc. (NASDAQ:RUBY) Simply Wall St. +6.03%
Mar-12-20 07:00AM	Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity GlobeNewswire -39.08%
Mar-03-20 04:01PM	Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast GlobeNewswire
Jan-30-20 08:00AM	Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria GlobeNewswire
Jan-14-20 08:33AM	BioMarin to Begin Early-Stage Study on Gene Therapy for PKU Zacks
Jan-13-20 02:30PM	'We will deliver in 2020,' Cambridge biotech CEO promises after 2nd trial disappointment American City Business Journals -5.57%
08:00AM	Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-08-20 08:00AM	Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer GlobeNewswire +5.22%
Jan-02-20 04:05PM	Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.53%
Dec-23-19 08:00AM	Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer GlobeNewswire +10.25%
Dec-21-19 07:18PM	Rubius Therapeutics, Inc. (RUBY): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-19-19 08:00AM	Flagship Unveils Newest Pioneering Platform: Ring Therapeutics PR Newswire -16.57%
Dec-18-19 08:05AM	Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors GlobeNewswire
Nov-14-19 08:00AM	Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress GlobeNewswire -19.92%
Nov-12-19 04:05PM	Rubius Therapeutics to Participate in Jefferies London Healthcare Conference GlobeNewswire -8.13%
08:00AM	Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary GlobeNewswire
Nov-08-19 07:00AM	Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Nov-05-19 04:05PM	Rubius Therapeutics to Announce Third Quarter 2019 Financial Results GlobeNewswire +12.92%
Nov-04-19 08:00AM	Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer PR Newswire -7.40%
Oct-28-19 02:56PM	Should You Buy Rubius Therapeutics, Inc. (RUBY)? Insider Monkey
Oct-17-19 08:00AM	Rubius Therapeutics Announces Oncology Poster Presentations at Upcoming Medical Conferences GlobeNewswire
Sep-03-19 04:05PM	Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire -5.28%
Aug-13-19 08:00AM	Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress GlobeNewswire
Aug-07-19 04:05PM	Rubius Therapeutics to Announce Second Quarter 2019 Financial Results GlobeNewswire
Jul-25-19 08:00AM	Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy GlobeNewswire
Jul-19-19 03:13PM	Investors Who Bought Rubius Therapeutics (NASDAQ:RUBY) Shares A Year Ago Are Now Down 44% Simply Wall St.
Jun-05-19 08:00AM	Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs GlobeNewswire
May-28-19 04:05PM	Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
May-23-19 05:27PM	Preclinical biotech Stoke Therapeutics plans $86M IPO American City Business Journals
May-15-19 08:00AM	Rubius Therapeutics Reports First Quarter 2019 Financial Results and Operational Progress GlobeNewswire
May-08-19 02:23PM	In slow year for life science IPOs, this venture firm is making big money American City Business Journals
May-06-19 04:05PM	Rubius Therapeutics to Announce First Quarter 2019 Financial Results GlobeNewswire
Apr-03-19 04:05PM	Rubius Therapeutics to Participate in Jefferies 6th Annual IO Cell Therapy Summit GlobeNewswire
Apr-02-19 08:00AM	Rubius Therapeutics Announces Extensive Preclinical Data for Three Red Cell Therapeutic Oncology Programs at the 2019 American Association for Cancer Research Annual Meeting GlobeNewswire +6.57%
Mar-28-19 08:00AM	Rubius Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results with Business Updates GlobeNewswire
Mar-25-19 12:15PM	How Many Insiders Bought Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares? Simply Wall St.
08:00AM	Rubius Therapeutics Appoints Natalie Holles to its Board of Directors and Greg Whitehead as Senior Vice President and Chief Quality Officer GlobeNewswire
Mar-19-19 04:05PM	Rubius Therapeutics to Announce Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire -7.53%
Mar-11-19 08:00AM	Rubius Therapeutics Announces FDA Clearance of Investigational New Drug Application for First-Ever Red Cell Therapeutic, RTX-134, for Treatment of Phenylketonuria GlobeNewswire
Feb-27-19 04:35PM	Rubius Therapeutics Announces Poster Presentations at the 2019 American Association for Cancer Research Annual Meeting GlobeNewswire
Feb-19-19 04:05PM	Rubius Therapeutics to Participate at Upcoming Investor Conferences GlobeNewswire -5.01%
Jan-07-19 08:00AM	Rubius Therapeutics Highlights Upcoming 2019 Milestones at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -8.05%
Dec-27-18 04:05PM	Rubius Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 12:15PM	Rubius Therapeutics, Inc. Secures $75 Million Loan Facility GlobeNewswire
Dec-17-18 04:05PM	Rubius Therapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-16-18 11:16PM	Qatar Fund Building Venture Capital Unit for U.S. Startups Bloomberg
Dec-06-18 08:54PM	Cambridge's Moderna sets record with $604M IPO American City Business Journals -5.18%
Nov-19-18 04:05PM	Rubius Therapeutics to Present at Evercore ISI HealthCONx Conference GlobeNewswire
Nov-13-18 08:00AM	Rubius Therapeutics Reports Third Quarter 2018 Financial Results and Operational Progress GlobeNewswire +19.35%
Nov-06-18 04:05PM	Rubius Therapeutics to Participate in Jefferies London Healthcare Conference GlobeNewswire
Nov-05-18 04:05PM	Rubius Therapeutics to Announce Third Quarter 2018 Financial Results GlobeNewswire
Sep-24-18 10:30AM	Biotech Market is Rolling and These Companies Need to Be on Your Radar ACCESSWIRE
08:41AM	Rubius (RUBY) in Focus: Stock Moves 8.7% Higher Zacks
Sep-20-18 04:05PM	Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire
Sep-14-18 04:05PM	Rubius Therapeutics Added to Russell 2000 and 3000 Indexes GlobeNewswire +10.12%
Sep-05-18 03:20PM	How This Biotech IPO Is Facing Off Vs. BioMarin In Metabolic Disease Investor's Business Daily -6.29%
Sep-04-18 04:05PM	Rubius Therapeutics to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
05:36AM	What you missed on your summer vacation in Mass. biotech news American City Business Journals
Aug-31-18 08:00AM	Rubius Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-21-18 04:05PM	Rubius Therapeutics to Announce Second Quarter 2018 Financial Results GlobeNewswire
Jul-25-18 08:30AM	Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics GlobeNewswire
Jul-24-18 07:44AM	[$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech The Wall Street Journal -8.13%
Jul-23-18 08:30AM	Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-20-18 07:30AM	[$$] Gormley's Take: Biotech Would-Be Acquirers Are Wary Buyers The Wall Street Journal +8.11%
Jul-18-18 11:02AM	Rubius Therapeutics shares surge 35% in trading debut MarketWatch
Jul-17-18 10:44PM	Rubius Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
OH ANDREW M.	Chief Financial Officer	May 15	Option Exercise	4.74	5,000	23,700	5,000	May 19 08:02 PM
Coughlin Christina M.	Chief Medical Officer	Apr 22	Buy	5.52	19,000	104,814	19,000	Apr 24 04:13 PM
CAGNONI PABLO J	CEO and President	Apr 14	Buy	4.70	21,000	98,694	21,000	Apr 15 05:14 PM
Epstein David R	Director	Mar 17	Buy	3.76	5,000	18,800	4,815,453	Mar 19 06:34 PM
Epstein David R	Director	Mar 13	Buy	3.91	10,000	39,100	4,810,453	Mar 17 05:59 PM
CARPENTER CHRISTOPHER L.	Chief Medical Officer	Dec 16	Option Exercise	2.87	48,000	137,760	82,843	Dec 18 07:50 PM
CARPENTER CHRISTOPHER L.	Chief Medical Officer	Dec 16	Sale	13.48	48,000	646,901	34,843	Dec 18 07:50 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience